Hanna Eriksson

Hanna Eriksson

Affiliated to Research | Docent
Visiting address: J6:20 BioClinicum, Akademiska stråket 1, 17164 Solna
Postal address: K7 Onkologi-Patologi, K7 Forskning Eriksson, 171 77 Stockholm

Research

  • Cutaneous melanoma is one of the deadliest forms of skin cancer. The survival
    is heterogenous both between and within disease stages. Early detection and
    surgical removal of the primary melanoma is still crucial for the prognosis.
    Landmark genomic and immunologic studies have translated into approved
    targeted treatments and immunotherapies for metastatic disease. Targeted
    therapies achieve high but often transient therapy responses. Immunotherapies
    can achieve durable responses in a subset of patients. Serious immune
    associated toxicities are a major clinical challenge.
    Our overall objective is therefore to optimally inform clinical
    decision-making and improve the outcome from early disease to advanced
    melanoma.
    Hanna Eriksson's Group | Karolinska Institutet (ki.se) [1]

Teaching

  • I am currently main-supervisor for PhD-students postodocs.
    PhD course organizer for:
    Clinical Oncology for Pre-Clinical Doctoral Students (#5505), Karolinska
    Institutet.
    Basic Course in Tumor Biology and Oncology (#3112), Karolinska Institutet.

Articles

All other publications

Employments

  • Affiliated to Research, Department of Oncology-Pathology, Karolinska Institutet, 2023-2026

Degrees and Education

  • Docent, Karolinska Institutet, 2021
  • Degree Of Doctor Of Philosophy, Department of Oncology-Pathology, Karolinska Institutet, 2013
  • University Medical Degree, Karolinska Institutet, 2002

Supervisor

  • Anna Oksanen, Loss of life expectancy for patients with malignant melanoma, by socioeconomic groups and sex, 2023

News from KI

Events from KI